CHMP turns down Lilly’s Emgality for cluster headacheAn EMA advisory panel has rejected expanding the use of Eli Lilly’s Emgality to include prevention of episodic Share XCHMP turns down Lilly’s Emgality for cluster headachehttps://pharmaphorum.com/news/chmp-turns-down-lillys-emgality-for-cluster-headache/
Lilly’s migraine drug gets key cluster headache approvalThe FDA has approved Eli Lilly’s Emgality (galcanezumab-gnlm) for the treatment of episodic cluster headache in adults, giving Share XLilly’s migraine drug gets key cluster headache approvalhttps://pharmaphorum.com/news/lillys-migraine-drug-gets-key-cluster-headache-approval/
Lilly claims fast FDA review for Emgality in cluster headacheEli Lilly has a battle on its hands in the migraine prevention category with third-to-market CGRP inhibitor Emgality Share XLilly claims fast FDA review for Emgality in cluster headachehttps://pharmaphorum.com/news/lilly-claims-fast-fda-review-for-emgality-in-cluster-headache/
Lilly drug scrapes through cluster headache trialFDA to make decision on Amgen drug tomorrow Share XLilly drug scrapes through cluster headache trialhttps://pharmaphorum.com/news/lillys-galcanezumab-scrapes-through-cluster-headache-trial/